Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of DoubleVerify Holdings, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm for more information [6]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that the company overbilled customers for ad impressions served to declared bots and that its risk disclosures were materially false and misleading [5]. - The lawsuit asserts that competitors were better positioned to incorporate AI into their offerings, adversely impacting DoubleVerify's profits and competitive standing [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Hims & Hers Health, Inc. common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and partnerships [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for purchasers of Hims common stock between April 29, 2025, and June 23, 2025, inclusive [1]. - Investors who purchased Hims stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Allegations Against Hims - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [5]. - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo, which was supposed to ensure continued access to Wegovy, and that positive statements were made about the partnership that misled investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of DoubleVerify Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customer ad spending to closed platforms where its capabilities were limited [5]. - It is claimed that DoubleVerify's high-margin Activation Services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5]. - The lawsuit also states that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and its risk disclosures were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements while concealing material adverse facts about the company's capital allocation priorities [4]. - Specifically, the lawsuit claims that the defendants concealed the importance of debt reduction following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. - Investors reportedly suffered damages when the true details about the company's financial priorities became public [4].

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased PepGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Hims & Hers Health, Inc. common stock during the specified Class Period, alleging misleading statements and failures to disclose critical information regarding partnerships and product offerings [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to common stock purchases of Hims & Hers Health, Inc. between April 29, 2025, and June 23, 2025 [1]. - The lawsuit claims that Hims made false and misleading statements about its collaboration with Novo Nordisk A/S, particularly regarding the availability of the weight-loss drug Wegovy and compounded semaglutide products [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that West made false and misleading statements regarding its business operations and financial health, leading to investor damages when the truth was revealed [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4] - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking in the top 4 for settlements since 2013 [4]

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Digimarc Corporation (NASDAQ: DMRC) between May 3, 2024 and February 26, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Digimarc securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified Class Period of the upcoming lead plaintiff deadline on July 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Digimarc Corporation, and investors who purchased securities between May 3, 2024, and February 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [2][5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success and recognition in the field [3]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [3]. Group 3: Case Allegations - The lawsuit alleges that Digimarc's management made false and misleading statements regarding a large commercial contract, which was not renewed on the same terms, adversely affecting the company's subscription and annual recurring revenue [4]. - The misleading statements led to investor damages when the true details about the contract and its implications were revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bitfarms Ltd. securities between March 21, 2023, and December 9, 2024, of the July 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Bitfarms securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 8, 2025 [2] - The lawsuit alleges that Bitfarms made false and misleading statements regarding its financial reporting and internal controls, leading to inaccurate financial statements that may need to be restated [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3]